Novel – Key Pax http://key-pax.com/ Tue, 22 Nov 2022 16:24:19 +0000 en-US hourly 1 https://wordpress.org/?v=5.9.3 https://key-pax.com/wp-content/uploads/2021/05/key-pax-icon-150x150.png Novel – Key Pax http://key-pax.com/ 32 32 Effects of implemented vaccine deployment strategies on the spread of SARS-CoV-2, the ensuing global burden of disease, and the emergence of new variants https://key-pax.com/effects-of-implemented-vaccine-deployment-strategies-on-the-spread-of-sars-cov-2-the-ensuing-global-burden-of-disease-and-the-emergence-of-new-variants/ Tue, 22 Nov 2022 15:52:00 +0000 https://key-pax.com/effects-of-implemented-vaccine-deployment-strategies-on-the-spread-of-sars-cov-2-the-ensuing-global-burden-of-disease-and-the-emergence-of-new-variants/

In a recent study published in natural medicineresearchers conducted a retrospective analysis to investigate the impact of vaccine sharing strategies on the heterogeneous global distribution of coronavirus disease 2019 (COVID-19) vaccines.

Study: Retrospective modeling of the effects of increased global vaccine sharing on the COVID-19 pandemic. Image Credit: M-Foto/Shutterstock

Background

During the early stages of the COVID-19 pandemic in early 2020, most countries relied on non-pharmaceutical interventions such as social distancing and lockdowns to reduce the spread of severe acute respiratory syndrome coronavirus 2 ( SARS-CoV-2). However, these mitigation strategies were socially and economically detrimental.

Unprecedented growth in vaccine technology has resulted in nearly 49% of the world’s population having received two primary doses of one of many COVID-19 vaccines by January 2022. However, global distribution coverage has been uneven, with nearly 90% of adults in many high-income countries being fully immunized, while middle- and low-income countries have significantly lower coverage.

Most low- and middle-income countries depend on vaccines donated by high-income countries or provided by World Health Organization (WHO) vaccine-sharing programs. However, having achieved nearly complete primary immunization coverage, most high-income countries are faced with the decision to extend their immunization program to the younger population and provide booster doses or donate excess vaccines to countries that need it.

While high-income countries have larger older populations, low-income countries lack the medical and economic resources to manage increased morbidity due to COVID-19 or apply non-pharmaceutical mitigation measures. Although some countries have succeeded in limiting the disease within their borders, the global spread and emergence of new variants can only be limited by reducing the number of global infections.

About the study

In the current study, researchers used a global model based on national-level SARS-CoV-2 vaccination and COVID-19 data from 152 countries to perform a retrospective evaluation to understand the effect of a shared increase in vaccines on the spread of the pandemic. The 152 countries have been divided into four income groups according to World Bank classifications. The model also accounted for the age-related dynamics of COVID-19 by incorporating each country’s demographic data, age-related susceptibility, symptoms and disease severity into the model.

The model simulated five vaccine sharing scenarios. The first was the current vaccine sharing scenario. Scenarios two, three, and four were where vaccines were shared after countries with vaccines had given two doses to 100% of their population, all individuals over 40, and the entire population over the age of 40. 65 years, respectively. The final scenario simulated the full sharing of vaccines to achieve global immunization of equal portions of each country’s population or the entire global elderly population.

The study also looked at two models of non-pharmaceutical interventions – one where compliance with mitigation protocols was not dependent on infection levels, and another where countries that donated more vaccines relaxed social restrictions more slowly to compensate for lower vaccination coverage. In addition, the proportion of each variant calculated from data from the Global Initiative on Sharing Avian Influenza Data (GISAID) database was incorporated into the model.

Results

The results indicated that increased vaccine sharing without adaptive non-pharmaceutical interventions would have reduced global deaths by 1.3 million during the COVID-19 pandemic, particularly in low-income countries. The simulations also revealed that additional measures, such as a slower easing of mitigation strategies by countries that donated more vaccines, could have further reduced the death rate.

Higher vaccine sharing would have reduced COVID-19 infections in low-, middle-, and high-income countries by 25.9%, 12.6%, and 15%, respectively, by mid-2021. The authors believe that increased sharing of vaccines during the early stages of the pandemic would have been more beneficial because the rapid spread of infection in countries without vaccine coverage would have generated population immunity, making delayed sharing of vaccines less efficient. Nevertheless, the sharing of vaccines remains necessary with the decrease in the effectiveness of vaccines and the emergence of variants evading immunity.

conclusion

To summarize, in this retrospective study, researchers used a global model based on data on COVID-19 vaccination coverage and SARS-CoV-2 infections in 152 countries to determine the effect of various scenarios of sharing vaccines on the spread of COVID-19, planned between early 2020 and late 2021.

Overall, the results indicated that increased vaccine sharing by vaccine-rich countries combined with adaptive mitigation measures where non-pharmaceutical interventions were slowly relaxed in countries that donated more vaccines would have significantly reduced COVID-19-related mortality by mid-2021. The authors proposed that for future pandemics, a vaccine sharing strategy based on need, not wealth, would benefit all countries.

]]>
DARPA seeks new approaches to improve mental health and prevent suicide https://key-pax.com/darpa-seeks-new-approaches-to-improve-mental-health-and-prevent-suicide/ Sat, 19 Nov 2022 06:32:57 +0000 https://key-pax.com/darpa-seeks-new-approaches-to-improve-mental-health-and-prevent-suicide/

Traumatic stress has caused a host of devastating effects for many service members, including mental illness, substance abuse, post-traumatic stress disorder, domestic violence, and suicide. Since September 11, 2001, more than 30,000 active duty personnel and veterans have committed suicide – a tragic toll that is four times the number killed in post-9/11 military operations.1 Developing effective approaches to preventing suicide is a top priority within the Department of Defence.

DARPA’s STRENGTHEN program, short for Strengthening Resilient Emotions and Nimble Cognition Through Engineering Neuroplasticity, aims to leverage recent advances in neuroscience and clinical practice to increase well-being and prevent or lessen the effects of traumatic stress. leading to behavioral health problems and suicidal behaviors. The program strives to achieve this by improving cognitive flexibility (CF) and emotional regulation (ER), key mechanisms of behavioral health that act as protective buffers against traumatic stress. FC refers to the mental ability to switch between thinking about two different concepts depending on the context of a situation. ER is a conscious or unconscious strategy for starting, stopping, or otherwise modulating the trajectory of an emotion. STRENGTHEN will attempt to identify, modulate and ultimately optimize the brain circuits responsible for CF and ER.

“Trauma and stress alter the function of brain networks, leading to the cognitive rigidity and emotional dysregulation associated with mental illness, addiction and suicide,” said Dr. Greg Witkop, a former Army surgeon, who manages the STRENGTHEN program within DARPA’s Office of Defense Science. . “Current approaches to mental health intervention rely on diagnostic categories based on descriptive symptoms rather than a mechanistic understanding of the brain network dysfunction underlying these symptoms. By identifying and optimizing brain networks associated with cognitive flexibility and emotional regulation, STRENGTHEN seeks to heal – and prevent – changes in brain networks caused by traumatic stress.

STRENGTHEN will strive to improve the mental protective mechanisms of CF and ED through two objectives: (1) the development of individualized brain network models of CF and ED and (2) the design of hybrid interventions to induce a neuroplastic change in the functional connectivity and/or structure of the CF and ER brain networks to optimize an individual’s CF and ER.

The STRENGTHEN program collaborates with the Center for Traumatic Stress Studies (CSTS) at the Department of Defense at the University of Uniformed Services in Bethesda, Maryland. The DARPA-CSTS partnership will harness the substantial literature and scientific expertise in the field of ER and CF to advance the nascent effort to link them in neurocognitive models. The joint effort uses the National Institute of Mental Health’s Research Domain Criteria research framework and will attempt to develop the first set of interventions to prevent and treat the psychological impact of traumatic stress – often referred to as invisible wounds. of war – and promote psychological health.

A STRENGTHEN Proposer Day for interested Proposers is scheduled for November 18, 2022. DARPA posted the STRENGTHEN Broad agency announcement on SAM.gov, which provides full program details.

Learn more about DARPA

]]>
Saudi Elenex will showcase world-class innovative ideas in the ever-evolving field of power and energy https://key-pax.com/saudi-elenex-will-showcase-world-class-innovative-ideas-in-the-ever-evolving-field-of-power-and-energy/ Wed, 16 Nov 2022 06:49:04 +0000 https://key-pax.com/saudi-elenex-will-showcase-world-class-innovative-ideas-in-the-ever-evolving-field-of-power-and-energy/

the kingdom of Saudi Arabia is recorded as having one of the highest per capita energy consumptions in the world with its growing population and rapid pace of industrialization. Electricity consumption in Saudi Arabia is three times the global average and has been growing at a compound annual growth rate of 6% in recent years. The total electricity transmission of Saudi Electricity Company (SEC) has also increased significantly, indicating a growing future demand for electricity and water in Saudi Arabia.

The government has announced a plan to install 41 GW of solar capacity and invest $109 billion in line with an overall plan to produce 54 GW by 2032. Saudi Arabia aims to continue increasing its generation capacity by electricity from 77 GW in 2014 to 156 GW by 2040.

Combined investment is highlighted to shift to renewable mechanisms such as solar, wind and nuclear energy sources. The plan is to secure half of the country’s electricity needs from alternative energy sources within the next 20 years.

Against this backdrop, the 23rd edition of Saudi Elenex is set to showcase world-class innovative ideas in the ever-evolving field of power and energy. The international exhibition for electricity, alternative energy, water and lighting technologies is a demonstration of unique discussions and exhibitions in the respected sector across Saudi Arabia.

Aligning with the progressive goals of Vision 2030the event aims to showcase the essentials of a key sector by including central discussions and encouraging the placement of unique inventions in energy technologies, transmission and distribution, solar energy technologies and services, as well as modern lighting products and technologies.

Every year, Saudi Elenex has grown in scale, creating an avalanche of innovative thinking across the world. Organized by REC, the pioneer and leading organizer of trade events and exhibitions in the Kingdom, this year’s event will be held from November 14-17, 2022 at the Riyadh International Convention and Exhibition Center alongside of Saudi Construction 2022which reflects on the construction sector and the main pioneering initiatives in the field.

Saudi Elenex will allow exhibitors to showcase products, services and technologies to thousands of corporate visitors representing multinationals, SMEs and large-scale organizations from Saudi Arabia, the GCC and around the world; but also gain insight into trends, challenges and budding projects in the sector through the help of keynote discussions and insightful dialogue with participating experts. Exhibitors will also have the opportunity to network with government officials, international buyers, consultants and industry specialists; create long-term and mutually beneficial partnerships with local businesses to launch joint ventures and projects of common interest; as well as to amplify the brand’s presence in the Saudi market and the wider Middle East region.

Visitors will also be able to explore the latest innovations, technological advancements and areas of R&D interest in the industry presented by international and local companies; interact with leading local, regional and international business representatives; network with influential decision makers and industry leaders who are equally enthusiastic about energy development in Saudi Arabia; identify profitable business prospects and arrange one-on-one meetings; as well as benefit from exclusive limited-time offers promoted by exhibitors and get information on the keynote discussions.

ABOUT REC: Riyadh Exhibitions Company (REC) was launched in 1980 in Riyadh, the main Arab center of the region, and has been a pioneer in the field of events in Saudi Arabia and the region by offering a wide range of organization services of events for trade shows, congresses, conferences and seminars. Since its inception, REC has planned and executed over 440 events spanning the country’s vital business and economic sectors.

FAIR USE POLICY
This material (including multimedia content) may not be published, broadcast, rewritten or redistributed. However, a direct link to the page (including the source, i.e. Marcopolis.net) is allowed and encouraged.

]]> Book talk: 3 entertaining crime novels https://key-pax.com/book-talk-3-entertaining-crime-novels/ Sun, 13 Nov 2022 03:02:38 +0000 https://key-pax.com/book-talk-3-entertaining-crime-novels/

Jeff Popple reviews three entertaining new crime novels from America. More of Jeff’s reviews can be found on his blog killermayhemandlongdogs.com

Livid by Patricia Cornwell

Sphere, $32.99

Veteran thriller author Patricia Cornwell provides another gripping entry in her series on Chief Medical Examiner Kay Scarpetta with her latest book, Livid. A controversial murder trial is interrupted when it is learned that the judge’s sister has been found dead, apparently the victim of a home invasion. Scarpetta rushes to the scene to find an unexpected and disturbing cause of death that reopens old wounds and new dangers. Cornwell is a confident, free-flowing writer, and again she delivers an intriguing plot, plenty of suspense, and an abundance of interesting forensic detail. His many fans will not be disappointed.

state of the treasury by CJ Box

Head of Zeus, $29.99

CJ Box is best known for his stellar series on game warden, Joe Pickett, but in recent years he’s been developing a second series on Montana private eye, Cassie Dewell. state of the treasury is the fifth book to feature Cassie, and it finds the investigator caught up in two cases involving a slippery crook and supposedly buried treasure. Cassie is an interesting, flawed character who goes about her business with an eye-pleasing professional ease. As always with a Box novel, the story unfolds smoothly and great interest is maintained through to the thrilling conclusion.

The resemblance by Lauren Nosset

Macmillan, $34.99

Unlike Box and Cornwell, Lauren Nossett is just beginning her career, but her first novel, The resemblance, is full of promise. Detective Marlitt Kaplan is first on the scene when a University of Georgia student is killed in a bizarre hit-and-run. The daughter of a college professor, Marlitt is caught up in old secrets and the sordid world of American college fraternities as she attempts to bring the abuser to justice. Battling pressure from influential parents of wealthy students, Marlitt understands how powerful fraternities are. An impressive start.

]]>
Gundam Witch From Mercury Prologue Novel appears in English https://key-pax.com/gundam-witch-from-mercury-prologue-novel-appears-in-english/ Thu, 10 Nov 2022 19:30:32 +0000 https://key-pax.com/gundam-witch-from-mercury-prologue-novel-appears-in-english/

The GundamInfo website has posted an official English translation of the Gundam Witch of Mercury prologue novel. You can read it immediately.

Title cradle planet, the tale is labeled as a novel, but it is more of a short story in terms of length. Ichiro Okouchi, screenwriter of the anime, wrote it. Okouchi has also contributed to series like Turn A Gundam, Azumanga Daioh, RahXephon, Code Geass, Valvrave the Liberator, Kabaneri of the Iron Fortress, Heavy Obect, Devilman Crybaby, and SK8 Infinity. Eriko Sugita translated the Gundam Witch of Mercury prologue novel in English from its original Japanese.

The story takes place after the prologue anime episode aired before the series premiere. You’ll have to watch it to get the necessary context.

The novel begins when the protagonist Suletta Mercury and her mother have moved to Mercury after the events of the prologue episode. The story is not written from the perspective of Suletta, but from that of Gundam Aerial, Suletta’s mobile suit. In the series proper, Suletta often refers to Aerial as a member of her own family, and the story illustrates why. The antenna seems to be smart. Aerial regards Suletta as her own sister. The Gundam Witch of Mercury The prologue novel details Aerial’s perspective as Suletta decides to attend Asticassia’s school of technology, though she is unaware of their mother’s plans to use her children for revenge against those who wronged them.

Mobile Suit Gundam: The Witch of Mercury airs on various streaming services and the GundamInfo YouTube channel.

]]>
Certa Therapeutics’ investigational drug FT011 offers breakthrough results as a potential new treatment for serious inflammatory and fibrotic diseases https://key-pax.com/certa-therapeutics-investigational-drug-ft011-offers-breakthrough-results-as-a-potential-new-treatment-for-serious-inflammatory-and-fibrotic-diseases/ Fri, 04 Nov 2022 12:00:00 +0000 https://key-pax.com/certa-therapeutics-investigational-drug-ft011-offers-breakthrough-results-as-a-potential-new-treatment-for-serious-inflammatory-and-fibrotic-diseases/
  • Research presented today by University of Michigan Medical School Highlights Breakthrough Treatment Potential of FT011 from Human Expression Profiles in Chronic Kidney Disease Study Supported by Animal Model Data
  • Research has demonstrated that treatment with FT011 results in a remarkable reversal of the activation of genetic markers associated with fibrosis
  • Fibrosis is responsible for 45% of all deaths worldwide – FT011 is a new drug that may treat chronic fibrosis in several organs such as kidneys, skin, lungs, heart and eyes
  • Certa Therapeutics is a clinical-stage biotechnology company based in Melbourne, Australiadeveloping innovative therapies for the treatment of fibrotic diseases

ANN ARBOUR, Mich. , November 4, 2022 /PRNewswire/ — A new study presented today by the University of Michigan reveals breakthrough results for Certa Therapeutics’ FT011, a potential new treatment for severe inflammatory and fibrotic diseases.

Results of a chronic kidney disease (CKD) study presented at Kidney Week 2022, the annual scientific meeting of the American Society of Nephrology, concluded that FT011 was highly effective in reversing marker activation molecules associated with fibrosis[1].

CEO of Certa Therapeutics, Professor Darren Kellyone of australia leading life science entrepreneurs and a leading expert in the study of fibrosis, said the findings are a critical breakthrough in the development of treatments for fibrosis – an unmet clinical need responsible for 45% of all deaths worldwide. industrialized world.

“These findings indicate significant promise for FT011 as a potential new therapeutic treatment for the treatment of fibrotic diseases and support our plans to advance this investigational drug into later-stage clinical trials,” said Professor Kelly. “The precision and insights gained from this transformative and disruptive research could change the way we identify and treat patients with chronic kidney disease.”

Comparative transcriptomic analysis with human kidney data identified potential predictive clinical profiles and biomarkers of patients most likely to respond to FT011 treatment for advanced kidney disease, including focal segmental glomerulosclerosis (FSGS) and membranous nephropathy (MN ). This analogous pattern of elevated gene activation is also present in an animal model of chronic kidney disease. Research has shown that treatment with FT011 for 12 weeks in this model significantly reduced the gene response associated with the fibrosis characteristic of the human disease. Therefore, the study indicates a likely positive response in human patients with chronic kidney disease.

The data was presented by Dr. Matthias Kretzler Research Team. Dr. Kretzler is a world renowned nephrologist, University of Michigan Faculty of Medicine Professor and Principal Investigator of the Network for the Study of Nephrotic Syndrome (NEPTUNE) – a leading research consortium of physician scientists at 26 sites in United States and Canada who develops innovative experimental strategies to improve the diagnosis, management and treatment of kidney disease.

NEPTUNE recruited a prospective, longitudinal and observational cohort of more than 650 renal failure patients with proteinuria and glomerular disease. NEPTUNE holds one of the largest clinical cohorts in the world that allows analysis of patients’ clinical, histological, genetic and molecular information, combined with patient long-term outcome profiles as part of the standard of care.

“Using this dataset, there is strong indication that treatment of patients with FT011 may mirror the positive impacts observed in the animal study by reversing the activation of molecular markers associated with fibrosis,” says Dr. Kretzler. “FT011 has demonstrated highly effective potential in the treatment of fibrotic disease. In my many decades of research, I have never seen such a significant result in our model regarding the potential of a drug to treat fibrosis in CRF.

Certa Therapeutics’ fibrosis research program has been in development for over 15 years. The company has identified and understood the genetic profile responsible for fibrosis, a significant scientific advance in the study of fibrotic diseases. FT011 is a new drug with the potential to treat chronic fibrosis in several organs such as kidneys, skin, lungs, heart and eyes.

“We have identified the fibrosis-linked biological receptor that gives us the potential to target fibrosis in a wide range of disease states,” Professor Kelly continues. “To our knowledge, there is no other drug on the market that does this.”

Key data from Certa Therapeutics’ Phase II trial in patients with scleroderma is expected to be published in early 2023.

AAbout Certa Therapeutics & FT011

Certa Therapeutics is a biotechnology company focused on improving lives by developing innovative precision treatments for inflammatory and fibrotic diseases.

Certa Therapeutics has designed a drug candidate platform and validated the role of a novel receptor that mediates signage pathways associated with inflammation and fibrosis. These targeted drug candidates have established proof of concept as potential treatments for multiple fibrotic diseases, including serious and chronic conditions affecting the kidneys, lungs, eyes, skin and heart. The impact on morbidity and mortality from fibrotic diseases is substantial, ultimately causing 45% of all deaths worldwide.

Certa Therapeutics seeks to combine these innovative therapies with biomarkers and genetic analyzes to identify patients most likely to benefit from treatment. Significant breakthroughs are urgently needed in this area, addressing a market that is worth more than US$15 billion annually.

Groundbreaking research by Certa Therapeutics has identified a novel biological target in the mechanism of fibrosis as a defined G-protein-coupled receptor (GPCR). This GPCR is silent in healthy tissue but activated following injury or disease. Evidence demonstrates the role of this GPCR on multiple downstream pathways causing inflammation and fibrosis. FT011 is a new drug that inhibits this GPCR, offering potential to treat chronic fibrosis in multiple organs.

Home

University of Michigan Medicine School Chronic Kidney Disease Initiative (CKDI)

As a research consortium of medical scientists across 33 sites in United States and Canadaalong with patient advocacy groups NephCure Kidney International, the Alport Syndrome Foundation and the Halpin Foundation, NEPTUNE strives to bring the latest research advances to patients diagnosed with focal segmental glomerulosclerosis (FSGS), minimal modification disease (MCD) and membranous nephropathy (MN), with the primary objective of using precision medicine for rare diseases.

NEPTUNE aims to understand the causes of Nephrotic Syndrome (NS) and has gathered information derived from clinical data, patient reported outcomes and information from kidney biopsy tissue, blood and urine samples. With this rich knowledge base, NEPTUNE will now move from observing the impact of NS on patients to finding new and effective ways to treat the disease. Most importantly, NEPTUNE will combine active disease triggers in a patient’s kidney with targeted clinical trials in pre-competitive partnerships with leading companies developing new treatments for NS.

NEPTUNE is a member of the Clinical Research Network on Rare Diseases (RDCRN). The RDCRN, an initiative of the National Center for Advancing Translational Sciences (NCATS), comprises 20 rare disease consortia that all strive to identify causes, risks of progression and potential new therapies for a wide range of rare diseases. diseases.

[1] S Eddy, et al., “Identification of non-invasive surrogates as predictors of response to FT011 in kidney disease” ASN Kidney Week 2022, abstract 3767783

SOURCE Certa Therapeutic

]]>
Launch day for Matthew Quick’s latest novel set in Nags Head – Up News Info https://key-pax.com/launch-day-for-matthew-quicks-latest-novel-set-in-nags-head-up-news-info/ Mon, 31 Oct 2022 12:10:14 +0000 https://key-pax.com/launch-day-for-matthew-quicks-latest-novel-set-in-nags-head-up-news-info/

Launch day for Matthew Quick’s latest novel set in Nags Head

Posted at 8:07 am on Monday, October 31, 2022

Publication day is a big day in an author’s life. For New York Times bestselling author Matthew Quick, November 1 is one of those days.

On this date, the new novel by Quick – we are the light – publishes with Simon & Schuster and has already been selected as the #1 Indie Next Pick for November 2022 by independent booksellers nationwide. It received rave reviews ahead of time and has a cover by Mitch Albom who calls it “a timely, charming, and at times heartbreaking novel of grief and hope”.

Quickly written The Silver Linings Playbook, which became a best-selling and Oscar-nominated film. He’s written seven additional novels, was named one of Hollywood’s 25 Most Powerful Authors by The Hollywood Reporter, received a PEN/Hemingway Award Honorable Mention, and had one of his YA books – kinda like a rock star – adapted for Netflix.

Get the latest headlines sent to you

For its launch day event, Quick will be speaking with Jamie Anderson, owner of Downtown Books, and signing books at the Keeper’s Galley event space at 101 Dove Street in Nags Head. The event starts at 6 p.m. Quick and Anderson will discuss the new book, life and writing. Quick will also answer questions from the public and sign copies of we are the light.

“This is the book we all need to read in 2022,” Anderson said. “In headline after headline, we heard of mass shootings in our malls, our schools, our communities. But what happens to these communities in the weeks, months, years after these tragedies occur – forever changing so many lives?

“Matthew Quick tackles this subject and explores the issue through the eyes of Lucas Goodgame, a movie theater shooting survivor who lost his wife, friends and neighbors in a scene that is all too familiar to us now – but which shouldn’t be. Worse still, his Jungian therapist Karl, a tremendous support for him, doesn’t see patients or respond to Lucas’ frequent calls, letters or visits to his home. So frequent in fact that the police have had to step in and create boundaries for him.

“His wife’s best friend tries to run the local restaurant and keep it sane; the shooter’s younger brother, a student Lucas had helped in his role as a high school guidance counselor, has set up camp in his backyard and his dead wife visits him every night losing feathers from his giant wings by handfuls,” Anderson continued. “we are the light is a book to read slowly, with great inspirations, taking into account each character, no matter how painful. It’s a book everyone should read everywhere because, as we’ve been reminded all year, what happens in Quick’s book, in the small town of Majestic, PA, can happen anywhere. where.

Quick and Anderson invite the Outer Banks community to join them in celebrating the release of this highly anticipated novel and launching we are the light in the world. For more information and details on this literary occasion, visit duckscottage.com or call 252-473-1056. Books can be pre-ordered for pick-up at the event and signed copies can be shipped after the event.

READ MORE NEWS HERE.

SUBSCRIBE TO COASTLAND TIMES TODAY!

]]>
Review: Edward J. Delaney’s Cary Grant’s LSD Novel ‘The Acrobat’ https://key-pax.com/review-edward-j-delaneys-cary-grants-lsd-novel-the-acrobat/ Fri, 28 Oct 2022 21:44:45 +0000 https://key-pax.com/review-edward-j-delaneys-cary-grants-lsd-novel-the-acrobat/

On the bookshelf

the acrobat

By Edward J. Delaney
Turtle Stitch: 280 pages, $18

If you purchase linked books from our site, The Times may earn a commission from Bookshop.org, whose fees support independent bookstores.

John Updike once described fame as “a face-eating mask”. As Edward J. Delaney’s biographical novel “The Acrobat” opens, it’s 1959 and Cary Grant is beginning to believe his beautiful cup has been irreversibly chewed away.

“He was always convincingly wrong, as actors always are,” Delaney writes of his subject. But as Grant contemplates the end of his career, his identity crisis has deepened. His character is too dignified and dapper to return to the kind of goofy roles that launched him, like “Bringing Up Baby” and “The Awful Truth.” But gravity also eludes him: he lost the role of Harry Lime in “The Third Man” and has little expectation for the Alfred Hitchcock thriller he has just finished, tentatively titled “In a Northwestern Direction.” Now, doing “Operation Petticoat”, he’s replaced by Tony Curtis. That leaves him with only one option, apparently: acid.

“The Acrobat” is presented as the story of Grant tunneling into his past via LSD, which he experimented with in the late 1950s with the encouragement of his third wife, Betsy Drake. The drug had not yet been banned in the United States, or even associated with the counterculture; acid trips were a bourgeois pursuit, much like the psychotherapy that guided Grant to drugs. (His trips to LSD have created irresistible cultural fodder lately: They played key roles in the 2017 documentary “Becoming Cary Grant” and the musical “Flying Over Sunset,” which ended a brief Broadway run. earlier this year.)

“You break free from the habitual self-imposed discipline,” Grant once said of LSD, and Delaney emphasizes a character eager to escape his gilded cage. As he stumbles, Grant reevaluates his past: chapters of ping-pong through time, from his vaudeville days to childhood, to walkie-talkies and middle-aged boredom, shuffling the narrative to evoke Grant’s search for a logical arc. It’s a clever way to structure a historical novel – and a more interesting way to write on LSD than to make the language all gooey and incessant. Delaney writes simply and beautifully about Grant.

Archibald Alec Leach had to put on masks early. He was the product of a broken home in Bristol, England – his alcoholic father told him his mother was dead, although decades later he learned she was institutionalized. Left to his own devices, he discovered theatre, working first as a stagehand and then as a vaudeville performer with a specialty in stilts and physical comedy. (Hence the novel’s title.) In 1920, he traveled to America, meeting Douglas Fairbanks and Mary Pickford on the bridge. Fairbanks offers a bit of advice that hints at the fragility of the actor’s personality: “Never touch your face.” Hint, hint.

The ‘Philadelphia Story’ and ‘His Girl Friday’ star was chatty and smiley, but Delaney imagines Grant as cautious and serious as a foul. In 1959, he asked a makeup artist friend to make him unrecognizable, to see if he could blend in. A trip to a restaurant, where a woman casually discusses it, suggests the idea is a success, but there is only more confusion in the triumph. . “Is he a fake, or does she see him at his truest?”

That same feeling that he hasn’t resolved himself as a person clouds his on-screen work; Grant cleaned up the fireplace space “where his Oscars are supposed to go, until they never come.” That’s also true of his friendships, mostly with reclusive guys like Howard Hughes and Greta Garbo. And it is true in his melancholic marriages, which he is accused of having contracted for money.

The dramatic plot of the novel, insofar as there is one, shows Grant becoming reckless and surly under the weight of it all: on a trip for “North by Northwest”, he reveals his acid trips to a journalist. Publicists sweat bullets; lawsuits and counter-lawsuits are threatened. But Delaney is more interested in Grant’s lack of fulfillment than its consequences. While doing vaudeville, he longs to “feel like there’s a place where I really belong”. In the 1930s, “greatness became him”, but he knows he is still on stilts. In the 1950s, he was wise enough to recognize the trap he found himself in: “He wants his own end in Hollywood, but the problem is that he actually lives in Hollywood.”

There is no shortage of novels dealing in exactly this kind of irony. The typical approach of the Hollywood novel consists in making fun of its veneers (“The Day of the Cricket” by Nathanaël West, “The Gambler” by Michael Tolkin); lamenting the way it treats its stars (“Blonde” by Joyce Carol Oates, “West of Sunset” by Stewart O’Nan); or to reveal it morally and criminally corrupt (LA Confidential by James Ellroy).

A man in a dark jacket is seated with his left hand against his right cheek, looking towards the camera.

Edward J. Delaney romances a crisis in Cary Grant’s life in “The Acrobat.”

(Beowulf Sheehan)

Delaney, who has written five acclaimed works of fiction before, is looking for something more subtle. He doesn’t satirize Grant or Hollywood so much as create a character that is effectively characterless. If Delaney clings too much to his mask metaphors, he’s also sensitive to how those masks change, how difficult they are to remove.

Had he wanted to, Delaney could have given his novel a happier, more Hollywood ending by looking beyond 1959. “North by Northwest” is eternally bolted to lists of the best movies of all time. In 1963’s “Charade,” Grant got the line every actor dreams of: “Do you know what’s wrong with you? Nothing.” He received an honorary Oscar and spent his final years doing laps of honor; he died while preparing for a Q&A with adoring fans.

But who could relate to that? “The Acrobat”, cleverly, represents the dark side of “stars, they are like us!” spills into gossip rags. It’s built around the notion that we all navigate life with uncertainty, that maybe one way we all look like celebrities is that we all have masks too. “Only those who suffer the same can see what the best part of him is,” Delaney writes – about fame. But in truth, the affliction is not knowing who we are behind our screens.

Athitakis is a Phoenix-based writer and author of “The New Midwest.”

]]>
DotLab shares key market research findings for its new DotEndo™ test https://key-pax.com/dotlab-shares-key-market-research-findings-for-its-new-dotendo-test/ Tue, 25 Oct 2022 23:13:00 +0000 https://key-pax.com/dotlab-shares-key-market-research-findings-for-its-new-dotendo-test/

Findings underscore the need to democratize and expand access to clinical diagnosis of endometriosis

NEW YORK, October 25, 2022 /PRNewswire/ — Today, DotLab shares key qualitative market research findings regarding receptivity and interest in the company’s new endometriosis diagnostics. The DotEndo™ test has been well received; most patients agreed that the test is relevant to their situation (86%), are interested in knowing more (96%), and would ask their OB/GYN about the test (84%). OB/GYNs and REIs surveyed expressed an unmet need for a reliable, widely available, and non-invasive test for endometriosis to triage patients to the appropriate treatment and/or specialists early on.

Symptoms of endometriosis clinically overlap with other conditions, often making it difficult to identify the disease. “It would be nice to have a [diagnosis] before proceeding with treatment, especially if it has side effects or potential morbidities,” said an OB/GYN who participated in the study.

Research indicates that if DotEndo™ has a low cost to the patient or is covered by insurance, doctors would use the test widely – and for the most part, DotEndo™ would be part of the initial workup. Similarly, nearly all patients said they would be interested in the test if it was within their desired price range, and 89% would pursue the test if it was covered by their insurance.

The research, carried out by a third party, was conducted on a sample of patients aged 18 to 49 (n = 800). Patients had >US$50,000 annual household income and were either fertility patients (n=399) currently seeking fertility treatments such as IVF or IUI, symptomatic patients (n=401) or without a diagnosis of endometriosis (n=201 ) or with a suspected or confirmed diagnosis of endometriosis (n=200). Primary market research interviews with 25 relevant providers were also included: 14 obstetricians/gynaecologists and 11 reproductive endocrinology and infertility (REI) specialists.

Patient Caitlin Hale, who was not involved in the research, said, “In hindsight, a prior diagnosis of endometriosis would have saved my family and me years of pain, confusion and financial stress.” She added that a non-invasive test could “transform the lives of patients with endometriosis by eliminating diagnostic delays and eradicating the normalization and stigmatization of menstrual pain.”

Through its technology, DotLab seeks to reduce the disparity of care for patients with endometriosis and shorten today’s decade-long diagnostic odyssey, opening the door to empirical treatment and appropriate referral.

About Dot Lab

Dot Laboratories, Inc. (“DotLab”) is a women-founded, women-led company solving some of the world’s most significant diagnostic challenges through the latest advancements in multiomics and computational biology. The company delivers clinical innovations in areas of high unmet need. The company is leveraging its expertise with new cutting-edge biomarkers and the power of machine learning to provide non-invasive testing, starting with endometriosis. The company is driving a paradigm shift in disease identification and management.

Media Contact: [email protected]
General contact details: [email protected]

SOURCE DotLab

]]>
The bookseller – News – Dialogue unveils Little’s first super main novel with a giant ‘spillboard’ https://key-pax.com/the-bookseller-news-dialogue-unveils-littles-first-super-main-novel-with-a-giant-spillboard/ Thu, 20 Oct 2022 07:46:42 +0000 https://key-pax.com/the-bookseller-news-dialogue-unveils-littles-first-super-main-novel-with-a-giant-spillboard/

Dialogue Books has unveiled a giant ‘spillboard’ in London revealing the cover of its 2023 super lead Rose water by gal-dem founder Liv Little.

Md Sharmaine Lovegrove edged Abigail Bergstrom’s first novel, described as a “remarkable, modern, multi-generational love story”, last year to Bergstrom Studio in a six-figure two-book deal.

Its giant ad is located at the Coldharbour Lane exit of Loughborough Junction station. Dialogue said: “Designed to make a statement about our intentions for the book, the board shows off that glorious cover in all its glory, along with wonderful endorsements from Bernardine Evaristo and Bolu Babalola, and facilitates pre-orders via a convenient QR Code. “

Little joined the unveiling herself, showing the cover to her 42,500 social media followers.

As part of the reveal, Dialogue worked with Jack Arts to organize a sampling stunt at the station where volunteers wearing branded t-shirts handed out bespoke bottles of rose-scented cosmetics with QR codes to rush hour travelers.

The team said: “We were kindly supported by Waterstones, which we tagged on the board itself and on these cosmetic bottles, capturing pre-orders and enticing readers to learn more about the book.”

The billboard will be in place for two weeks from publication and will kick off the first hardback campaign for Dialogue’s new future as a standalone division within Hachette.

]]>